Similar to SEMA3C’s role in mediating intrinsic resistance of PCa to targeted RTK therapies, SEMA3C may also play a role in facilitating acquired resistance of cancer to RTK targeted agents. The gene discussed is SEMA3C; the disease is posterior cortical atrophy.